Q-omics provides the consensus-scored UNC93A profile across patient tissues and cancer cell-line models. UNC93A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, UNC93A is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, UNC93A RNA expression shows 10,462 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, COAD, and TGCT as cancer lineages where UNC93A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC93A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC93A survival associations across molecular data types. UNC93A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC93A RNA expression–survival associations across cancer types. High UNC93A expression shows unfavorable associations in KICH, BRCA, SKCM, BLCA and COAD, but favorable associations in ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for UNC93A RNA expression.
This table summarizes UNC93A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for UNC93A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC93A shows lower tumor expression in KICH and HNSC and higher tumor expression in COAD, UCEC, LUAD and LUSC. The COAD box plot shows higher UNC93A RNA expression in tumor versus normal tissue (log2 FC = +2.046, t-test p < 0.001).
This table shows molecular features associated with UNC93A in patient tissues and cancer cell lines. In patient samples, UNC93A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UNC93A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
